Naltrexone Neuroimaging in Teens with Eating Disorders

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 17, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

June 30, 2027

Conditions
Eating DisordersBinge EatingPurging (Eating Disorders)Bulimia NervosaAnorexia Nervosa, Atypical
Interventions
DRUG

Naltrexone

Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.

DRUG

Placebo

Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.

Trial Locations (1)

64108

RECRUITING

Children's Mercy Research Institute, Kansas City

All Listed Sponsors
collaborator

University of Kansas Medical Center

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Children's Mercy Hospital Kansas City

OTHER